THE FOLLOWING are brief sketches that describe the professional training and experience, particularly as they relate to the KDOQI Blood Pressure Management in CKD Clinical Practice Guidelines, as well as principal academic affiliations of the work group members. All work group members completed a disclosure statement certifying that any potential conflict of interest would not influence their judgment or actions concerning the KDOQI.
Lawrence Agodoa, MD, is Director, End Stage Renal Disease Program for the National Institutes of Health. He received his Fellowship in Nephrology and Rheumatology from the University of Washington. He is currently an Attending Physician, Nephrology Services at Walter Reed Medical Center. Dr Agodoa’s areas of research and special interest are in hypertension and end-stage renal disease.
Sharon Anderson, MD, is Professor of Medicine Oregon Health and Science University, Division of Nephrology. She completed a Fellowship in Nephrology at Brigham and Women’s Hospital and Harvard Medical School. Her areas of research and interest are in hypertension and the kidney, pathophysiology of the kidney, diabetic nephropathy, hormonal modulation of renal function, and mechanisms of progressive glomerular injury. Dr Anderson has received research grants from Genzyme, Juvenile Diabetes Foundation, Merck, and Polycystic Kidney Research Foundation. She is on the National Kidney Foundation’s CKD Advisory Board.
Sharon P. Andreoli, MD, is Professor of Pediatrics at Indiana University Medical Center, James Whitcomb Riley Hospital for Children. She completed a Fellowship in Pediatric Nephrology at Indiana University. Dr Andreoli’s area of research or special interest is hemolytic uremic syndrome, oxidant injury, dialysis, pediatric nephrology, and clinical pediatric nephrology. Dr Andreoli has served as Councilor and is currently Secretary-Treasurer of the American Society of Pediatric Nephrology. She has served as Councilor and is currently an Assistant Secretary for the International Pediatric Nephrology Association. Dr Andreoli has also served on several National Kidney Foundation committees, including serving as chairman of fellowship grant review committee. She is a member of the NKF Scientific Advisory Board, the KDOQI Support group, and the ASN/NKF Ad Hoc Committee for development of collaborative research initiatives. Dr Andreoli has received grants from the NIH, Baxter Healthcare Corporation, and Genentech.
George R. Bailie, MSc PharmD, PhD, is a Professor of Pharmacy Practice at Albany College of Pharmacy. His specialty in research is pharmacotherapeutics and pharmacokinetics in CKD and dialysis. He has published numerous original research papers, chapters, reviews, and cases in the medical and pharmacy literature. He serves on the editorial board for Peritoneal Dialysis International and is a regular reviewer for many nephrology journals. He has been honored with several awards, including Educator of the Year and Researcher of the Year awards, New York State Chapter of ACCP, and Fellow of the Royal Pharmaceutical Society of Great Britain, in recognition of sustained original contributions to pharmaceutical knowledge. He has received research grants from Renal Research Institute, Inc., National Kidney Foundation of North East New York, and Baxter Healthcare. Dr Bailie has also served as a consultant and speaker for several pharmaceutical companies, including Amgen. He is a director of Nephrology Pharmacy Associates, Inc.
George L. Bakris, MD, is Professor of Preventive Medicine and Internal Medicine, the Vice Chairman of the Department of Preventive Medicine and the Director of the Hypertension/Clinical Research Center at Rush Presbyterian, St. Luke’s Medical Center. He previously served as Director, Renal Research at Ochsner Clinic and Director, Nephrology Fellowship Program at University of Texas, San Antonio. Dr Bakris serves as a NKF representative for the JNC 6 and JNC 7 and is a Board Certified Specialist in Hypertension. He has received numerous NIH grants for controlled trials, including AASK, the Hypertension Genetics (SCOR), and the K30, Clinical Trials Center awards. Dr Bakris has received research funds or grants from Abbott, Aventis, Boehringer Ingelheim, Bristol-Myers Squibb, Forest, Merck, Novartis, Pfizer, and Pharmacia.
Kline Bolton, MD, FACP, is Professor of Medicine at University of Virginia in Charlottesville, where he is Chief of the Division of Nephrology and Director of the Nephrology Clinical Research Center, Kidney Center, and Renal Operations. He has received special honors from organizations ranging from the American Society for Clinical Investigation to the International Society of Nephrology. He has published many articles in journals, ranging from the American Journal of Kidney Diseases and Kidney International to Immunologic Renal Diseases, and has contributed to numerous textbooks, including the Textbook of the Autoimmune Diseases and the Textbook of Nephrology. Dr Bolton is Chairman of the Renal Physicians Association Work Group on Appropriate Preparation of Patients for Renal Replacement Therapy. In addition, Dr Bolton serves on the Advisory Boards for Amgen and Ortho-Biotech. His research interests are in refining the epitope(s) involved in causing Goodpasture’s syndrome, treating glomerulonephritis, and disease management of CKD and ESRD.
Mary Beth Callahan, ACSW, LCSW, is a Nephrology Social Worker at the Dallas Transplant Institute. She serves on the Network #14 Medical Review Board and the Life Options Rehabilitation Advisory Council. She formerly served as CNSW chair and as a Kidney Health Program Advisory Board member for the Texas Department of Health. Her areas of research include quality of life measurement, rehabilitation, adherence, and outcome-driven nephrology social work practice. Ms Callahan was honored with the Distinguished Service Award from the National Kidney Foundation.
Jeffrey A. Cutler, MD, MPH, is Senior Scientific Advisor, Division of Epidemiology and Clinical Applications (DECA), National Heart, Lung, and Blood Institute (NHLBI). He is involved with many NHLBI studies and is a member of their governing committees, including the Steering Committee for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and the Executive Committee for the Trials of Hypertension Prevention (TOHP). Dr Cutler has received several rewards from the US Public Health Service, including two Commendation Medals, an Outstanding Service Medal, and a Meritorious Services Medal. His areas of research and special interest are the prevention and treatment of hypertension, the prevention of other cardiovascular diseases, controlled trials’ methods, and nutrition. Dr Cutler is affiliated with the American Heart Association, the American Public Health Association, the Society of Epidemiological Research, the Council on Epidemiology and Prevention—World Heart Federation, and the American College of Preventive Medicine.
Jane H. Greene, RD, CSR, is the renal nutritionist and clinical instructor at Vanderbilt University Medical Center. She has served on the Board of Director for the End Stage Renal Disease Network 8 and the National Kidney Foundation of Middle Tennessee. She has researched and authored several scientific articles on topics related to nutrition and chronic kidney disease.
Tom Hostetter, MD, is a senior scientific adviser and director of the National Kidney Disease Education Program at the National Institute of Diabetes and Digestive and Kidney Diseases. He is also professor of medicine on leave from the University of Minnesota, where he was director of the renal division in the department of internal medicine for 15 years. He received his bachelor’s degree in chemistry from Yale University. After graduating from Baylor College of Medicine, Dr Hostetter served his internship at Baylor and the remainder of his residency at the Peter Bent Brigham Hospital. Following his nephrology fellowship at the Brigham, he stayed as a member of the faculty of Harvard Medical School. Dr Hostetter’s major research interest is in the mechanisms of progressive renal disease. He has served on several editorial boards, General Medicine B study section of the NIH, the Nephrology board of the American Board of Internal Medicine, and the councils of the American and International Societies of Nephrology and was president of the American Society of Nephrology from 1999 to 2000.
Cynda Ann Johnson, MD, MBA, is professor and dean of the Brody School of Medicine at East Carolina University. She is past president of the American Board of Family Practice and was recently elected as Vice President of the American Board of Medical Specialties. She is on the Steering Committee of NKDEP and the Advisory Board of KDOQI of the NKF.
James P. Lash, MD, is an Associate Professor of Clinical Medicine and the Program Director of the Nephrology Fellowship at the University of Illinois. His research interests include chronic renal insufficiency, hypertension, transplant, and diabetic nephropathy. He has participated in a number controlled trials, including the African-American Study of Kidney Disease and Hypertension (AASK) and the RENAAL Study. He is currently a Co-Investigator for the AASK Cohort Study and a Principal Investigator for the Chronic Renal Insufficiency Cohort (CRIC) Study. Dr Lash has received research funds from Merck Research Labs.
Andrew S. Levey, MD, (Work Group Chair), is Dr Gerald J. and Dorothy R. Friedman Professor of Medicine at Tufts University School of Medicine and Chief of the William B. Schwartz, MD Division of Nephrology at Tufts-New England Medical Center, Boston. His research is mainly in the areas of epidemiology of CKD and cardiovascular disease in CKD, controlled trials to slow the progression of CKD, clinical assessment of kidney function, assessment and improvement of outcomes in dialysis and transplantation, and clinical practice guideline development and implementation. Dr Levey is currently Program Director for an NIDDK-funded clinical research training program, “Clinical Trials, Epidemiology and Outcomes Research in Nephrology.” He is past Chair of the Clinical Science Committee of the American Society of Nephrology. He is past Chair of the National Kidney Foundation’s Task Force on Cardiovascular Disease in Chronic Renal Disease and KDOQI Work Group on Chronic Kidney Disease: Evaluation, Classification and Stratification. Dr Levey is the recipient of the National Kidney Foundation’s President Award of 1998 and Garabed Eknoyan Award of 2002. He is the Director of the newly formed KDOQI Center for Clinical Practice Guideline Development and Implementation at Tufts-New England Medical Center.
Peter A. McCullough, MD, MPH, FACC, FACP, FAHA is Consultant Cardiologist and Chief of Nutrition and Preventive Medicine at William Beaumont Hospital in Royal Oak, Michigan. Dr McCullough has over 200 published scientific communications. His principal research interest is in how CKD works as a cardiovascular risk state. Dr McCullough serves as an editorial consultant for the Journal of the American College of Cardiology and is an Associate Editor of Reviews in Cardiovascular Medicine.
Edgar R. Miller III, MD, PhD, is the Assistant Professor of Medicine and Epidemiology at John Hopkins University School of Medicine and the Bloomberg School of Public Health. Dr Miller completed a fellowship in General Internal Medicine at Johns Hopkins and is a faculty member in the Welch Center for Prevention, Epidemiology and Clinical Research. Dr Miller’s research has focused on the prevention and treatment of hypertension and CKD through both nonpharmacological and pharmacological approaches. His current studies are funded by the American Heart Association (lifestyle intervention for the treatment of hypertension in the elderly) and the NIH (African-American Study of Kidney disease—cohort study). He practices General Internal Medicine at the Johns Hopkins Outpatient center and serves as a Hypertension Specialist designated by the American Society of Hypertension.
Joseph V. Nally, MD, is Director of the Nephrology Fellowship Program at the Cleveland Clinic Foundation. He completed his Fellowship in Nephrology at the University of Pennsylvania Hospital. Dr Nally is on the ACP-MKSAP Writing Committee and is also a representative for the National Kidney Foundation Medical Advisory Board to the American College of Physicians. Dr Nally has been a speaker for Amgen, Merck, and Novartis. His area of research is with the National Institute of Health’s Studies of Renal Vascular Hypertension.
John D. Pirsch, MD, is Director of Medical Transplantation Service and is Professor of Medicine at the University of Wisconsin Medical School. Dr Pirsch has received research funds or grants from Fujisawa Healthcare Inc., MedImmune Inc., Novartis Pharmaceuticals, Roche Pharmaceuticals, and SangStat. His areas of research are in primary care and long-term complications of the transplant recipient and new immunosuppressive drugs.
Ronald J. Portman, MD, is Professor of Pediatrics and Director of the Division of Pediatric Nephrology and Hypertension at the University of Texas-Houston Medical School. He completed his Fellowship in Pediatric Nephrology at Washington University School of Medicine and St. Louis Children’s Hospital. Dr Portman has been an active Journal Reviewer and has published over 100 papers. He is the Chairman of the Executive Committee of the International Pediatric Hypertension Association and is an ASH Clinical Hypertension Specialist. He is a member of the American Society of Nephrology, the Southwest Pediatric Nephrology Study Group, the American Society of Pediatric Nephrology and the International Pediatric Nephrology Association. He is also an Associate Member of the American Board of Pediatrics, a member of the ASN Hypertension Advisory Council, and a member of the Medical Advisory Committee to the Cardio-renal Section of the FDA. His community service has led him to Co-Direct Pediatric Dialysis Camp and to be a member of the Medical Advisory Board of the National Kidney Foundation of Southeast Texas and of the Medical Review Board of ESRD Network 14 of Texas. He reports research grants from Boerhinger-Ingelheim, King, AstraZenica, Pfizer, and Novartis.
Michael V. Rocco, MD, MSCE, is a Professor of Medicine and Nephrology at Wake Forest University School of Medicine in Winston-Salem, North Carolina. He received his MD degree at Vanderbilt University in Nashville, Tennessee and also served his Internal Medicine residency at Vanderbilt. He completed a nephrology fellowship at the University of Pennsylvania in Philadelphia, Pennsylvania and received a master’s degree in epidemiology at Wake Forest University. He was the Principal Investigator at Wake Forest for the NIH-sponsored HEMO Study and was the chair of the Nutrition Committee for this study. He is the principal investigator for the NIH Frequent Hemodialysis Network for clinical trials in daily nocturnal hemodialysis. He serves as the Vice-Chair for the National Kidney Foundation’s KDOQI. He is also a member of the CMS ESRD Clinical Performance Measures Quality Improvement Committee and is chair of the peritoneal dialysis subcommittee. He has more than 70 peer-reviewed manuscripts in the areas of hemodialysis, peritoneal dialysis, nutrition, chronic renal failure, and epidemiology.
Mary Ann Sevick, ScD, RN, is an Associate Professor in the School of Nursing at the University of Pittsburgh. She also serves as Affiliate faculty in the Center for Bioethics and Health Law at the University of Pittsburgh. She has published numerous articles in scientific journals such as the Journal of the American Dietetic Association, Peritoneal Dialysis International, American Journal of Nephrology, Preventive Medicine, American Journal of Preventive Medicine, and American Journal of Health Behavior. She has also presented at many national and international proceedings or conferences. She has participated in numerous NIH-funded studies involving behavior change interventions and is Principal Investigator on studies examining the effectiveness of adherence enhancement interventions in persons with type 2 diabetes and also individuals receiving maintenance hemodialysis.
Domenic Sica, MD, is Professor of Medicine and Pharmacology at the Medical College of Virginia of Virginia Commonwealth University. He received a Nephrology Fellowship from the University of Texas. Dr Sica’s areas of research and special interest are minority health-care issues as relates to hypertension and/or renal disease. He has received research funds or grants from Bristol-Myers Squibb, Sanofi-Syntheolabo, Novartis, Biovail, and Reliant.
Donald E. Wesson, MD, is Chairman, Department of Internal Medicine at Texas Tech University of Health Science Center. He received his Fellowship in Nephrology. Dr Wesson’s area of research and special interest is in Acid-Base progression of CKD. He received a research grant from Minority Health and Education Research Grant Program.